Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Status:
Not yet recruiting
Trial end date:
2022-06-05
Target enrollment:
Participant gender:
Summary
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and
Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual
tablets in Healthy Subject